Conference Highlights ASH

R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies.
Using the Swedish and Danish Lymphoma Registries from 2000 to 2011––which included over 95% of all diagnosed lymphoma patients in Sweden and Denmark––the study authors obtained novel data about the prognostic factors and primary treatment of mantle-cell lymphoma (MCL).
Vincristine sulfate liposome injection (VSLI; Marqibo) was developed to optimize vincristine pharmacokinetics, dose-intensification, and target-tissue delivery.
Oral arsenic trioxide (ATO) was originally developed for the treatment of relapsed acute promyelocytic leukemia. In this study, Gill and colleagues investigated the use of an oral ATO-based regimen for patients with relapsed or refractory mantle-cell lymphoma (MCL).
New treatment options are needed for relapsed or refractory non-Hodgkin lymphoma (NHL), particularly mantle-cell lymphoma (MCL), where there are no curative options.
In this preclinical research effort, Zhang and colleagues showed that various subunits of immunoproteasome are highly expressed in mantle-cell lymphoma (MCL) cells.
Use of rituximab maintenance therapy prolongs progression-free survival (PFS) and overall survival (OS) in patients with mantle-cell lymphoma (MCL) after conventional chemotherapy treatment.
Supported by the French LYSA (Lymphome Du Manteau 2010 SA) group, this prospective phase 2 trial evaluated the efficacy and safety of a 4-drug combination known as RiBVD (rituximab, bendamustine, bortezomib, and dexamethasone) in elderly patients with previously untreated mantle- cell lymphoma (MCL), including patients older than 65 years or patients who were not eligible for autologous stem-cell transplantation.
Mantle-cell lymphoma (MCL) is a disease of the elderly; the median age at diagnosis is 70 years. Currently, the standard therapy for elderly patients has not been defined. In this trial, Jerkeman and colleagues investigated whether the addition of lenalidomide (LEN) to bendamustine plus rituximab (BR) followed by LEN maintenance for 7 months would improve the efficacy and safety of treatment among older patients with MCL.
Lenalidomide, an immunomodulatory compound that targets both tumor cells and the tumor microenvironment, has shown clinical efficacy either alone or in combination with rituximab in relapsed mantle-cell lymphoma (MCL).
Page 1 of 4
Results 1 - 10 of 34
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME